CircRAD23B promotes proliferation and carboplatin resistance in ovarian cancer cell lines and organoids.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University and in conformity with the Declaration of Helsinki of the World Medical Association. All patients signed written informed consent. Competing interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Competing interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding This work was supported by the National Nature Science Foundation of China (81872119) and the Postgraduate Research & Practice Innovation Program of Jiangsu Province (SJCX21_0622)."